



Oceanaa Biotek Industries Limited

Regd. Off.

15, Zackaria Colony, 4th Street, Choolaimedu,
Chennai - 600 094, India.

Corp. Off.

6, 1st Floor, Wellington Estate,
53, Ethiraj Salai, Egmore, Chennai - 600 008. India.

T : + 91 44 3024 1900 F : + 91 44 3024 1990

E : obil@oceanaabiotek.com

CIN : L15549TN2005PLC057919

OBIL/BSE/151/2017-2018

13th February, 2018

To,
The Corporate Relations Department
The Bombay Stock Exchange Ltd,
P J Towers, 1st Floor,
Dalal Street,
Mumbai - 400 001

Dear Sir/Madam,

Ref: Scrip Code: **538019**

ISIN: **INE732P01018**

Sub: Submission of Standalone Unaudited Financial Results for the quarter ended 31st December, 2017.

This is to inform you that the meeting of the Board of Directors was held on 12th February, 2018 which was extended to 13th February, 2018 for requirement of additional information inter alia, to consider and approve the Unaudited (limited reviewed) Financial Results for the quarter ended 31st December, 2017.

In this regard, the following documents are enclosed herewith:

- Standalone Unaudited Financial Results for the quarter ended 31.12.2017 - Regulation 33 - Annexure I of SEBI (LODR) Regulations, 2015.
- Limited review report signed by the Statutory Auditor

The meeting commenced at 04:00 p.m. on 12th February, 2018 and concluded at 02:00 p.m. on 13th February, 2018

Kindly update the above in your records.

Thanking You.

For Oceanaa Biotek Industries Limited

Vimalla Joseb
Managing Director
Encl: As above

Laboratory : Pudukkuppam Village,
Mandavai Post, Marakkanam,
Tindivanam Taluk, Villupuram District,
Tamil Nadu 604 303.

Tel : + 91 4147 302300

www.oceanaabiotek.com



Oceanaa Biotek Industries Limited

Regd. Off.

15, Zackaria Colony, 4th Street, Choolaimedu,
Chennai - 600 094, India.

Corp. Off.

6,1st Floor, Wellington Estate,
53, Ethiraj Salai, Egmore, Chennai - 600 008. India.

T : + 91 44 3024 1900 F : + 91 44 3024 1990

E : obil@oceanaabiotek.com

CIN : L15549TN2005PLC057919

To
The Board of Directors,
Oceanaa Biotek Industries Limited
No. 15, Zackaria Colony, 4th street,
Choolaimedu, Chennai – 600 094,
Tamil Nadu

Dear Sir/Madam,

We hereby confirm the following in respect of the unaudited financial statements for the quarter ended on 31st December, 2017 being presented before the Board at the meeting to be held on 12th February, 2018.

- (1) That to the best of our knowledge, the financial results do not contain any false or misleading statement of figures.
- (2) That to the best of our knowledge, the financial results do not omit any material fact which may make the statements or figures contained therein misleading.

Yours sincerely

Place: **Chennai**

Date: **12.02.2018**



Vimalla Joseb
Managing Director
DIN: 00849207

Laboratory : Pudukuppam Village,
Mandavai Post, Marakkanam,
Tindivanam Taluk, Villupuram District,
Tamil Nadu 604 303.
Tel : + 91 4147 302300
www.oceanaabiotek.com

M/S. OCEANAA BIOTEK INDUSTRIES LIMITED
CIN: L15549TN2005PLC057919
NO.15, ZACKARIA COLONY, 4TH STREET,
CHOO LAIMEDU, CHENNAI - 600094, TAMIL NADU

Statement of Standalone UnAudited Results for the quarter and period ended 31.12.2017

in lakhs except earnings per share and share information/data

Part I



Quarter and Period ended 31/12/2017

S.No	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Nine Months Ended		Previous Year ended
		31st December'2017	30th September'2017	31st December'2016	31st December'2017	31st December'2016	31st March' 2017
		Unaudited	Unaudited	Audited	Unaudited	Audited	Audited
	Revenue from Operations						
I.	(a) Income from Operations	1,545.12	1,387.91	954.12	3,873.59	3,291.53	3,645.00
II.	(b) Other Income (net)	1.79	1.55	0.73	7.40	0.84	4.05
III.	Total Revenue	1,546.91	1,389.46	954.85	3,881.00	3,292.37	3,649.05
IV.	Expenses						
	a. Purchase of stock-in-trade	937.25	878.20	709.92	2,216.82	2,004.51	2,057.88
	b. Changes in inventory of finished goods	-28.54	-38.47	-23.47	179.38	75.51	48.78
	c. Employee benefit expenses	44.43	44.06	48.07	121.94	158.20	196.08
	d. Finance costs	3.31	1.32	0.74	5.54	1.85	2.46
	e. Depreciation and amortisation expenses	85.49	82.36	27.43	248.21	82.50	110.25
	f. Other expenses	81.04	110.82	126.06	376.00	607.50	803.92
	Total Expenses	1,122.98	1,078.28	888.77	3,147.90	2,930.07	3,219.37
V.	Profit/(Loss) before exceptional and extraordinary items and tax (I-IV)	423.93	311.18	66.09	733.10	362.31	429.67
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit / (Loss) before extraordinary items and tax (V-VI)	423.93	311.18	66.09	733.10	362.31	429.67
VIII.	Extraordinary Item	-	-	-	-	-	-
IX.	Profit before tax (VII-VIII)	423.93	311.18	66.09	733.10	362.31	429.67
X.	Tax expense						
	1 Current tax	38.50	38.50	33.01	115.50	108.87	164.17
	2 Deferred tax	7.06	7.06	-	21.18	-	-9.48
XI.	Profit / (Loss) for the period from continuing operations (VII-VIII)	378.38	265.63	33.07	596.42	253.44	274.98
XII.	Other Comprehensive Income						-9.12
XIII.	Profit / (Loss) from discontinuing operations	-	-	-	-	-	-
XIV.	Tax expenses of discontinuing operations	-	-	-	-	-	-
XV.	Profit / (Loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-	-
XVI.	Profit (Loss) for the period (XI+XIV)	378.38	265.63	33.07	596.42	253.44	265.86
XVII.	Reserves excluding Security Premium, Revaluation & General Reserves	427.83	314.66	334.73	427.83	334.73	176.54
XVIII.	Earnings per equity Share						
	(1) Basic	2.79	1.96	0.32	4.40	2.48	2.70
	(2) Diluted	2.79	1.96	0.32	4.40	2.48	2.70
	See accompanying notes to the financial statements.						

Notes:


- The Unaudited Financial results were reviewed by the Audit Committee and taken on record by the Board of directors at their meeting held on 12th February, 2018 which was extended to 13th February, 2018
- Figures of the previous period/year are reclassified / regrouped or rearranged wherever necessary to make it comparable.
- There are no separate reportable segments for the nine months ended as per Accounting Standard 17 on segment reporting notified under the Companies (Accounting Standard) Rules 2014.
- There were no Investors' Complaints pending/received during the period.

For and on Behalf of Board of Directors



Vimalla Joseb
 Managing Director
 DIN:00849207

Place: Chennai
Date : 13/02/2018

PROFIT RECONCILIATION						
Rs. In Lakhs						
Sl. Particulars	Quarter Ended 31/12/17	Quarter Ended 30/09/17	Nine Months Ended 31/12/17	Quarter Ended 31/12/16	Nine Months Ended 31/12/16	Year Ended 31/03/17
1 Net Profit as per Previous GAAP (Indian GAAP)	322.74	215.88	512.39	48.72	203.09	270.08
2 Increase in changes in inventory values due to Ind AS	46.12	40.23	55.45	-15.65	50.35	-6.1
3 Deferred Tax expense as per Ind AS Adjustments	9.52	9.52	28.56	0	0	1.88
Net Profit After Tax as per Ind AS	378.38	265.63	596.4	33.07	253.44	265.86





Limited Review Report

Review Report to
The Board of Directors
M/s Oceanaa Biotek Industries Limited

We have reviewed the accompanying statement of unaudited standalone financial results of M/s Oceanaa Biotek Industries Limited for the quarter ended December 31, 2017 and the year to date results for the period April 1, 2017 and December 31, 2017 together with the notes thereon attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. CIR/CFD/FAC/62/2016 dated July, 05 2016.

The preparation of statement in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July, 05 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principle laid down in the applicable Indian Accounting Standards (IND AS) specified under Section 133 of the Companies Act, 2013 read with relevant Rules issued there under other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/FAC/62/2016 dated July, 05 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Chennai
Date: 13th February, 2018

For Elangovan & Co.
Chartered Accountants
Firm Regn. No. 006990S



S. Sathish Kumar
S Sathish Kumar
Partner
M.No: 226384